文献速递睡眠呼吸障碍

热塑成型与定制下颌前移器治疗阻塞性睡眠呼吸暂停:随机非劣效性试验

Heat-moulded versus custom-made mandibular advancement devices for obstructive sleep apnoea: a randomised non-inferiority trial.
PubMed 文献 · Thorax · 2019-05-03

这项多中心开放随机对照试验纳入198例拒绝或不耐受CPAP的OSA患者,比较热塑成型可调式下颌前移器(ONIRIS)与定制丙烯酸下颌前移器(TALI)治疗2个月的疗效。符合方案分析显示,TALI组应答率51.7%,ONIRIS组53.6%,绝对差1.9%(90%CI:11%至15%),在预设20%非劣效界值内,表明热塑成型装置短期非劣效于定制装置。

要点

  • 热塑成型可调式MAD在2个月时对OSA的疗效非劣效于定制丙烯酸MAD。
  • 两组在严重程度、症状、生活质量和血压下降方面的效果相同。
  • ONIRIS组报告更多副作用,而TALI组依从性略好。

核心结论

  • 在拒绝或不耐受CPAP的OSA患者中,热塑成型可调式MAD短期非劣效于定制丙烯酸MAD。

研究设计与样本

  • 多中心、开放、随机对照非劣效性试验,纳入198例拒绝或不耐受CPAP的OSA患者,随机分配至热塑成型可调式装置或定制丙烯酸装置治疗2个月,按中心和OSA严重程度分层。

主要发现

  • 符合方案分析中,TALI组应答率51.7%,ONIRIS组53.6%,绝对差1.9%(90%CI:11%至15%),在预设20%非劣效界值内。
  • 两组在严重程度、症状、生活质量和血压下降方面的效果相同。
  • ONIRIS组报告更多副作用,TALI组依从性略好。

关键数值与推荐

  • 主要非劣效结局为2个月时AHI较基线下降≥50%或AHI<10次/小时。
  • 非劣效界值预设为符合方案分析中两组主要结局差异20%。

临床怎么用

  • 对于拒绝或不耐受CPAP的OSA患者,热塑成型可调式MAD可作为定制MAD的短期替代选择。
  • 处方热塑成型MAD时需注意其副作用报告更多,应监测依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Custom-made mandibular advancement devices (MADs) are reported as providing higher efficacy rates compared with thermoplastic heat-moulded MADs but at the price of higher costs and treatment delays. OBJECTIVE: To determine whether a thermoplastic heat-moulded titratable MAD (ONIRIS; ONIRIS SAS, Rueil Malmaison, France) is non-inferior to a custom-made acrylic titratable MAD (TALI; ONIRIS SAS, Rueil Malmaison, France) for obstructive sleep apnoea (OSA). METHODS: We conducted a multicentre, open, randomised controlled trial of patients with OSA refusing or not tolerating continuous positive airway pressure (CPAP). Participants were randomly assigned to a thermoplastic heat-moulded titratable device or a custom-made acrylic device for 2 months with stratification by centre and OSA severity. The non-inferiority primary outcome was a ≥50% reduction in apnoea-hypopnoea index (AHI) or achieving AHI <10 events/hour at 2 months. The non-inferiority margin was preset as a difference between groups of 20% for the primary outcome in the per-protocol analysis. MAIN RESULTS: Of 198 patients (mean age 51 [SD, 12] years; 138 [72.6%] men; mean body mass index 26 [SD, 2.7] kg/m2; mean AHI 26.6/hour [SD, 10.4]), 100 received TALI and 98 ONIRIS. In per-protocol analysis, the response rate was 51.7% in the TALI group versus 53.6% in the ONIRIS group (absolute difference 1.9%; 90% CI: 11% to 15%, within the non-inferiority margin). Effectiveness was the same for severity, symptoms, quality of life and blood pressure reduction. Patients in ONIRIS group reported more side effects and adherence was slightly better with TALI. CONCLUSION: In patients with OSA refusing or not tolerating CPAP, the thermoplastic heat-moulded titratable MAD was non-inferior in the short-term to the custom-made acrylic MAD. TRIAL REGISTRATION NUMBER: NCT02348970.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Pépin JL, Raymond N, Lacaze O, et al. Heat-moulded versus custom-made mandibular advancement devices for obstructive sleep apnoea: a randomised non-inferiority trial. Thorax. 2019. PMID: 31053619. doi:10.1136/thoraxjnl-2018-212726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。